Literature DB >> 6746662

Cytochrome b, flavins, and ubiquinone-50 in enucleated human neutrophils (polymorphonuclear leukocyte cytoplasts).

R Lutter, R van Zwieten, R S Weening, M N Hamers, D Roos.   

Abstract

Neutrophilic granulocytes contain an oxidase system in their plasma membrane that can be activated to generate superoxide radicals and hydrogen peroxide. Cytochrome b, flavoprotein, and ubiquinone-50 have been proposed as components of this oxidase system. These components have been quantitated, but the results are obscured by different isolation procedures for plasma membranes from resting and activated neutrophils. This problem has now been avoided by the use of enucleated neutrophils (polymorphonuclear leukocyte cytoplasts), which are almost completely devoid of intracellular structures but contain an intact, activatable oxidase system (Roos, D., Voetman, A.A., and Meerhof, L.J. (1983) J. Cell Biol. 97, 368-377). Membranes of resting and phorbol myristate acetate-stimulated cytoplasts contain equal amounts of cytochrome b (4 pmol/milliunit of alkaline phosphatase) and also equal amounts of noncovalently bound FAD (2 pmol/milliunit of alkaline phosphatase). These findings refute the hypothesis that incorporation of cytochrome b and/or a flavoprotein into the plasma membrane constitutes the mechanism of activation of the oxidase system. Ubiquinone-50 is present neither in intact neutrophils nor in cytoplasts, excluding a role for this compound in the generation of bactericidal oxygen species by neutrophils.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746662

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Separation and function of neutrophil karyogranuloplasts and comparison with cytoplasts and intact cells.

Authors:  Y Ohno; J Falloon; B E Seligmann; J Nath; M M Friedman; J I Gallin
Journal:  Inflammation       Date:  1987-09       Impact factor: 4.092

2.  Distinct patterns of granulocyte luminol-dependent chemiluminescence response to lectins WGA and RCA-I.

Authors:  K E Magnusson; C Dahlgren; A Sjölander
Journal:  Inflammation       Date:  1988-02       Impact factor: 4.092

3.  Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?

Authors:  D J Morré; C Kim; M Paulik; D M Morré; W P Faulk
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

Review 4.  Subcellular localization and dynamics of components of the respiratory burst oxidase.

Authors:  N Borregaard
Journal:  J Bioenerg Biomembr       Date:  1988-12       Impact factor: 2.945

5.  NADPH oxidase of guinea-pig macrophages catalyses the reduction of ubiquinone-1 under anaerobic conditions.

Authors:  M Murakami; M Nakamura; S Minakami
Journal:  Biochem J       Date:  1986-07-15       Impact factor: 3.857

6.  Regulation of superoxide generation by myeloperoxidase during the respiratory burst of human neutrophils.

Authors:  S W Edwards; T F Swan
Journal:  Biochem J       Date:  1986-07-15       Impact factor: 3.857

7.  NADPH-binding component of the superoxide-generating oxidase in unstimulated neutrophils and the neutrophils from the patients with chronic granulomatous disease.

Authors:  T Umei; K Takeshige; S Minakami
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

Review 8.  The NADPH oxidase of professional phagocytes--prototype of the NOX electron transport chain systems.

Authors:  Andrew R Cross; Anthony W Segal
Journal:  Biochim Biophys Acta       Date:  2004-06-28

Review 9.  NADH oxidase of plasma membranes.

Authors:  D J Morré; A O Brightman
Journal:  J Bioenerg Biomembr       Date:  1991-06       Impact factor: 2.945

10.  Cytochrome b deficiency in an autosomal form of chronic granulomatous disease. A third form of chronic granulomatous disease recognized by monocyte hybridization.

Authors:  R S Weening; L Corbeel; M de Boer; R Lutter; R van Zwieten; M N Hamers; D Roos
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.